Blocking VISTA using immunoenhancing antibodies leads to increased infiltration of tumour-specific T cells, a decrease in MDSC numbers and suppressive capacity and a decrease in tumour-specific Tregs [102]. This evidence concerns the gene VSIR and neoplasm.